NEW Proven Method To Slow Progression of Nearsightedness
Millions of children across the US are poised to benefit from a breakthrough therapy that addresses the fast-growing issue of myopia (nearsightedness), which is projected to negatively affect more than 50 percent of the world’s population by 2050. MiSight® 1 day has been shown to reduce myopia progression by more than half versus a single-vision one-day lens. Over three years, children wearing MiSight® 1 day had 59 percent less myopia progression and 52 percent less axial elongation on average than those wearing a single-vision one-day lens.
The correlation between increasing myopia and potentially vision-threatening complications later in life is well established and is a growing concern for both eye care practitioners and parents worldwide. Here in the United States, the rate of myopia occurrence has increased from 25% to 42% over the last two generations. This is due to a combination of genetic and lifestyle factors. Looking long-term, myopia significantly increases the risk of retinal detachment and myopic maculopathy, with even low myopia levels associated with a higher prevalence of glaucoma and cataracts.
This convenient, daily disposable contact lens is well-accepted by children and does not affect their daily activities. It is designed to be worn for ten or more hours per day, six or more days per week to get the maximum treatment effect.
Vision Source is fortunate enough to have three Coopervision-certified optometrists, one in each of our locations, namely, Dr. Vuong in Greenway Galleria, Dr. Parker at our Deerbrook location, and Dr. Lin in our Willowbrook office. Only Coopervision-certified optometrists may prescribe MiSight lenses. This is really quite a feat as there are not many certified providers in CooperVision’s Brilliant Futures™ Myopia Management Program in the Houston area. The cornerstone of this comprehensive approach to myopia management in pediatric patients is the MiSight® 1-day contact lens – the first and only contact lens approved by the FDA for slowing the progression of myopia, in children who are between 8 and 12 years old at the initiation of treatment.
If your child has issues with nearsightedness, click the link below to make an appointment and we will assist you in determining whether they are a candidate for this amazing new therapy.